This new report by Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the European nonvascular stents market. Major topics covered by this report include a discussion of current and emerging nonvascular stenting technologies; a clinical overview of nonvascular conditions targeted by stenting, and an analysis of the European markets for biliary, esophageal, tracheobronchial, and urologic (including ureteral and urethral/prostatic) stents.
EXECUTIVE SUMMARY i. Stent Design ii. Procedure Volumes iii. Market Analysis a. Biliary Stents b. Esophageal Stents c. Tracheobronchial Stents d. Urologic Stents e. Combined Market Forecast Exhibit ES-1: Europe, Nonvascular Stent Placements, Combined Procedure Volumes Forecast, 2010-2015 Exhibit ES-2: Europe, Nonvascular Stents, Combined Market Forecast, 2010-2015 1. CURRENT AND EMERGING PERIPHERAL VASCULAR AND NONVASCULAR STENTING TECHNOLOGIES 1.1 Stent Design 1.1.1 Vascular Stents 1.1.2 Nonvascular Stents 1.1.3 Stent Deployment Mechanisms 1.2 Stent Materials 1.2.1 Metal 188.8.131.52 Absorbable Magnesium Alloys 184.108.40.206 Cobalt Alloys 220.127.116.11 Nickel-Titanium Alloys 18.104.22.168 Stainless Steel 1.2.2 Standard Polymers 1.2.3 Biodegradable Polymers 1.3 Stent Coatings 1.3.1 Radiopacity Enhancement 1.3.2 Biocompatibility Enhancement 1.3.3 Active Therapeutic Enhancement 22.214.171.124 Drug-Eluting Stents 126.96.36.199.1 Antirestenotic Efficacy 188.8.131.52.2 Drug Delivery Techniques 1.3.4 Stent Coverings and Linings Exhibit 1-1: Selected Biomedical, Clinical, and Technical Stent Requirements Exhibit 1-2: Advantages and Disadvantages of Selected Vascular Stent Designs Exhibit 1-3: Advantages and Disadvantages of Metal Stent Materials Exhibit 1-4: Selected Polymeric Stent Materials Exhibit 1-5: Selected Characteristics of Antirestenosis Agents Used in Drug-Eluting Stents Exhibit 1-6: Advantages and Disadvantages of Nonresorbable and Biodegradable Polymeric Drug Carriers for Drug-Eluting Stents 2. OVERVIEW OF STENTING FOR NONVASCULAR APPLICATIONS 2.1 Bile Duct Diseases 2.1.1 Benign Biliary Strictures 2.1.2 Malignant Biliary Strictures 2.1.3 Treatment 2.2 Esophageal Diseases 2.2.1 Benign Esophageal Strictures 2.2.2 Malignant Esophageal Strictures 2.2.3 Treatment 184.108.40.206 Nonsurgical Treatment 220.127.116.11 Surgical Treatment 2.3 Renal System Diseases 2.3.1 Benign Urethral and Prostatic Strictures 2.3.2 Malignant Urethral and Prostatic Strictures 2.3.3 Treatment 2.4 Tracheobronchial System Diseases 2.4.1 Benign Tracheobronchial Strictures 2.4.2 Malignant Tracheobronchial Strictures 2.4.3 Treatment 18.104.22.168 Expandable Metal Stents 22.214.171.124 Silicone Stents 3. EUROPEAN NONVASCULAR STENTS MARKET 3.1 Biliary Stents 3.1.1 Products and Technologies 3.1.2 Market Analysis 3.1.3 Competitive Analysis 3.2 Esophageal Stents 3.2.1 Products and Technologies 3.2.2 Market Analysis 3.2.3 Competitive Analysis 3.3 Tracheobronchial Stents 3.3.1 Products and Technologies 3.3.2 Market Analysis 3.3.3 Competitive Analysis 3.4 Urologic Stents 3.4.1 Products and Technologies 126.96.36.199 Ureteral Stents 188.8.131.52 Urethral (or Prostatic) Stents 3.4.2 Market Analysis 3.4.3 Competitive Analysis 3.5 Combined Market Analysis 3.5.1 Market Drivers 3.5.2 Market Limiters 3.5.3 Combined Market Forecast Exhibit 3-1: 2012, Europe, Selected Biliary Stents Exhibit 3-2: Europe, Biliary Stent Placements, Procedure Volumes Forecast, 2010-2015 Exhibit 3-3: Europe, Biliary Stents, Market Forecast, 2010-2015 Exhibit 3-4: 2010, Europe, Biliary Stents Market, Share by Supplier Exhibit 3-5: 2012, Europe, Selected Esophageal Stents Exhibit 3-6: Europe, Esophageal Stent Placements, Procedure Volumes Forecast, 2010-2015 Exhibit 3-7: Europe, Esophageal Stents, Market Forecast, 2010-2015 Exhibit 3-8: 2010, Europe, Esophageal Stents Market, Share by Supplier Exhibit 3-9: Advantages and Disadvantages of Metal and Silicone Tracheobronchial Stents Exhibit 3-10: 2012, Europe, Selected Tracheobronchial Stents Exhibit 3-11: Europe, Tracheobronchial Stent Placements, Procedure Volumes Forecast, 2010-2015 Exhibit 3-12: Europe, Tracheobronchial Stents, Market Forecast, 2010-2015 Exhibit 3-13: 2010, Europe, Tracheobronchial Stents Market, Share by Supplier Exhibit 3-14: 2012, Europe, Selected Urologic Stents Exhibit 3-15: Europe, Urologic Stent Placements, Procedure Volumes Forecast, 2010-2015 Exhibit 3-16: Europe, Urologic Stents, Market Forecast, 2010-2015 Exhibit 3-17: 2010, Europe, Urologic Stents Market, Share by Supplier Exhibit 3-18: Europe, Nonvascular Stent Placements, Combined Procedure Volumes Forecast, 2010-2015 Exhibit 3-19: Europe, Nonvascular Stents, Combined Market Forecast, 2010-2015 4. COMPANY PROFILES 4.1 Abbott Laboratories 4.2 C.R. Bard, Inc. 4.3 Boston Scientific Corporation 4.4 Cook Group, Inc. 4.5 ev3, Inc./Covidien, Inc. 4.6 W.L. Gore & Associates, Inc. 4.7 Johnson & Johnson 4.8 Medtronic, Inc. APPENDIX: COMPANY LISTING